BioMarin Pharmaceuticals has raised expectations for its dwarfism product BMN-111 (vosoritide) on the back of strong Phase II data.
In the study in 26 children, BMN-111 demonstrated a favorable safety profile and efficacy at the 15µg/kg daily dose. The...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
